Other advanced therapies, in this case using cell derivative nanoparticles that are under clinical evaluation (Phase I), comprise iExosomes, extracellular vesicles loaded with siRNA for the specific inhibition of KRAS G12C in pancreatic cancer (NCT03608631) [45]. The gene discussed is KRAS; the disease is pancreatic neoplasm.